



Vaccines and Global Health: The Week in Review
31 October 2020 :: Number 577
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents *[click on link below to move to associated content]*

- A. [Milestones :: Perspectives :: Featured Journal Content](#)
- B. [Emergencies](#)
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)



Milestones :: Perspectives :: Research

.....
.....

Funding for COVID-19 Vaccines, Treatments Fastest Way to Save Lives, Economy, Secretary-General Tells World Health Summit, Urging Global Solidarity

25 October 2020 SG/SM/20364

Following is UN Secretary-General António Guterres' message to the virtual World Health Summit, in New York today:

The COVID-19 pandemic is the greatest crisis of our age. Just seven months since it was declared, over 1 million people have died, and tens of millions have been infected. Cases are still rising, and new spikes and waves are occurring in places that had suppressed the virus for many months.

The indirect impact of the pandemic is wreaking havoc on societies and economies. Travel restrictions and lockdowns have resulted in the loss of 500 million jobs so far and are costing the global economy some \$375 billion every month.

Reports of gender-based violence are skyrocketing. Mental illness is a crisis within a crisis. Deaths from other health conditions are likely to increase, as resources are redirected towards COVID-19. Some 24 million children could drop out of school, with life-long impact. COVID-19 is driving us even farther off course from achieving the vision and promise of the 2030 Agenda for Sustainable Development.

The first hard lesson of this crisis is that we were not prepared. Global health and emergency response systems have been tested and found wanting. Access to health is a human right denied to billions of people around the world.

Universal health coverage is the path to high-quality, equitable, affordable health care. Strong public health systems and emergency preparedness are essential steps to greater resilience. All countries have signed up to universal health coverage by 2030. But, we cannot wait 10 years. We need health systems that work, before we face an outbreak of something more contagious than COVID-19, more deadly or both.

The second lesson is that we are not powerless. If we follow the science, and demonstrate unity and solidarity, we can overcome the pandemic. Public health measures, including masks, physical distancing and hand-washing, are proven means of keeping the virus at bay.

We need to protect the vulnerable - older people and those with pre-existing conditions. We must stop holding and attending events that amplify the spread of the virus; and we must work with communities on sharing information and building trust.

Numerous Governments have demonstrated that taking targeted, local measures immediately outbreaks occur can stamp them out. At the same time, we must persevere with

comprehensive public health measures that the World Health Organization (WHO) identified on day one: find, isolate, test and care for cases, and trace and quarantine their contacts.

Third, we need global solidarity every step of the way. Developed countries must support health systems in countries that are short of resources. And we must join together as Governments, the private sector, civil society and all partners, to make sure vaccines, tests and treatments are available to everyone, everywhere. A vaccine must be a global public good.

Fully funding the ACT-Accelerator is the fastest way to end the pandemic. Vaccines, tests and therapies are more than life savers. They are economy savers and society savers.

There is no choice between saving people's lives and saving jobs. Protecting people from the virus is the best way to keep schools open and businesses running. It will prevent the virus from spreading even more widely and returning in wave after wave.

But, as I have said before, there is no panacea during a pandemic. Relief will come not through one single step, but through smartly combining cutting-edge research with basic public health.

The fourth lesson is that misinformation and disinformation are deadly allies of the virus. They are contributing to deaths and infections, and to social tensions that have led to violence. Unless we counter rumours, conspiracy theories and lies, they will negate our other efforts.

The United Nations "Verified" campaign aims to ensure people have access to accurate advice that protects and promotes health. I welcome efforts by social media platforms and others to prevent the spread of false stories and advice, and promote scientific, fact-based analysis — although more needs to be done.

The World Health Summit and the M8 Alliance are important platforms to champion and work together for global health. This gathering, bringing together science, politics, business and civil society, is the place to build new partnerships, share best practices and take decisions that could save lives. Let us use this opportunity to confront the COVID-19 crisis together, with the urgency and integrity it requires. Thank you.

.....
.....

[IFFIm Prices US\\$500 Million 3-year Benchmark Vaccine Bonds](#)

London, 29 October 2020 – The International Finance Facility for Immunisation Company (IFFIm) today priced US\$500 million, 3-year fixed rate benchmark **Vaccine Bonds that will provide Gavi, the Vaccine Alliance, flexible funding for its core immunisation programmes and efforts to develop and distribute eventual COVID-19 vaccines to countries around the world, particularly the poorest.**

The transaction will mature on 6 November 2023, has a re-offer price of 99.821%, and carries a semi-annual coupon of 0.375%. This is IFFIm's first US\$ benchmark bond since its US\$300 million 3-year floating rate bond in November 2017. Citi, Crédit Agricole CIB, and TD Securities are lead managers of the transaction.

"As the world confronts a devastating pandemic, this latest Vaccine Bond issuance is giving Gavi the financing it needs to act quickly, boldly and flexibly," said IFFIm Board Chair Cyrus Ardan. "These bonds enable private sector investors to directly contribute to a critical effort to address one of the biggest global challenges we face."

"IFFIm's Vaccine Bonds have long been an indispensable tool that allows Gavi to do what is necessary to ensure the availability of vaccines to the world's poorest children," said **Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance**. **"This latest issuance will give Gavi the financial headroom to continue that core work, which has been complicated by the COVID-19 pandemic, as well as to play an essential role in the global collaboration to develop and equitably distribute eventual COVID-19 vaccines around the world."**

"We are pleased to see a robust response from investors for IFFIm and Gavi to support vaccine development and distribution in response to COVID-19," said Jingdong Hua, Vice President and Treasurer of the World Bank, IFFIm's Treasury Manager. "Investors are making a critical contribution to vaccine availability in the poorest countries, while benefitting from a uniquely impactful investment opportunity and the strong credit quality of the issuer."

The diversified and high-quality orderbook reflects the appeal of the IFFIm mission with global investors. Geographic placement was 52% for Europe, Middle East and Africa and 40% for the Americas with the remaining 8% placed with Asian investors. Central banks and official institutions took 60%, asset managers, pension funds and insurance funds made up 26% and banks, bank treasuries and corporates rounded out the book with 14%...

.....
.....

[COVAX welcomes appointment of civil society representatives](#)

Geneva, 30 October 2020 – As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO) – welcomes the appointment of civil society organisation (CSO) representatives to key COVAX working groups. The involvement of civil society has been crucial in public health campaigns in recent years – in promoting access to health products, engaging with the public, and expanding the reach of public health organisations in rolling out programmes around the world.

The representatives were selected by a civil society selection committee made up of members from 10 civil society organisations from 7 countries and 4 continents. The ten nominees were selected from a pool of 159 candidates based on a range of criteria: technical expertise, CSO experience and connectedness, knowledge of immunization and engagement of CSOs in the immunization space, and the detailed technical criteria outlined in the call for applications for each workstream. Gender and geographical diversity were also taken into consideration. In addition, all candidates were thoroughly assessed by the COVAX workstream leads and leadership.

The selected representatives will be involved in a number of key groups working contributing to the only global solution for equitable access to COVID-19 vaccines for the most vulnerable groups around the world. The ten civil society and community representatives will provide valuable technical expertise and use their experiences to play an important role in the success of COVAX.

The list of appointed civil society representatives is as follows:

WORKING GROUP	NAME	ORGANISATION
Covax Coordination Meeting	Messin Teklu Tessema	IRC
Access/Allocation	Karrar Karrar	Save the Children
Vaccine Strategy	Jane Barratt	International Federation on Aging
CRD Coordination	Kathleen Clark	IFRC
CRD – Communication, Advocacy, Training	Carla Toko	VillageReach
CRD – Demand	Robert Kanwagi	World Vision
Manufacturing SWAT	Alain Alsalhani	MSF
Enabling Science SWAT	Sheetal Sharma	Safari Doctors
Clinical Development and Operations SWAT	Farah Kumar	Aga Khan Foundation
Technical Review Group	Rebecca Grais	MSF

.....

COVID-19 Vaccines: World Bank Country Financing/Oversight

Editor’s Note:

In our edition of 17 October 2020, we reported on a World Bank Group [WBG] announcement of a **USD\$12 billion “envelope for developing countries to finance the purchase and distribution of COVID-19 vaccines, tests, and treatments for their citizens.”**

In a supporting document – [WBG VACCINE ANNOUNCEMENT– KEY FACTS](#) – **the World Bank noted that it “will help client countries develop appropriate criteria for making the selected vaccine available to all their citizens.”** This document references a “consensus to first target health workers, other essential workers, and priority groups such as the elderly, people with co-morbidities, and others at high risk from COVID-19” **and added that “the**

Bank will ensure that the allocation mechanisms within countries are fair and equitable.”

Given the number of active COVID-19 vaccine allocation frameworks and guidance documents, the role of multilateral collaborations such as COVAX, and varying regulatory and recommending bodies, we found this stated role ensuring that allocation is fair and equitable to be quite interesting.

The Center for Vaccine Ethics and Policy [CVEP] raised five questions about this oversight role with the World Bank. The questions and the WBG answers are presented below:

[1] [CVEP] Will WBG be using any specific "active" normative guidance [WHO Values Framework; COVAX allocation framework, NSAEM Framework, country-level allocation strategies, etc.] to define/guide what "fair and equitable" will mean in a country's allocation mechanisms? If not, will WBG create its own guidance?

[WBG] Country allocation strategies will be appraised for their alignment with the WHO Fair Allocation Framework before Bank financing for vaccine purchase will be committed.

[2] [CVEP] Would the vaccine allocation "formula/strategy" be specified in the financing terms of the World Bank "grants, credits, and loans" that might be employed in any given country situation?

[WBG] There is no predetermined allocation of financing to countries. Countries will decide the amounts within their IBRD/IDA allocations, and will access the financing on their applicable country specific IDA or IBRD financing terms.

[International Bank for Reconstruction and Development/International Development Association]

[3] [CVEP] What WBG governance/review mechanism will be employed to assess/confirm that the allocation approach proposed by the country is, indeed, fair and equitable? What monitoring mechanism will ensure that the allocation plan is executed adequately in that regard?

[WBG] The Bank will appraise the client's overall vaccination strategy, including its specific allocation approach, before committing financing for vaccine purchases. The appraisal of the allocation framework will consider alignment with the WHO Fair Allocation Framework as well compliance with Bank risk management frameworks and policies as applicable, such as the Environmental and Social Framework. Bank teams will supervise implementation of the project and provide implementation support to the client as in any Bank-financed operation, including to monitor compliance with the agreed allocation plan.

[4] [CVEP] Does WBG intend to take a position on COVID-19 vaccine program elements beyond "fairness and equitable access"? Such elements would include requirements for a consent process [at least where a vaccine is still investigational [EUA without Phase III data/not yet licensed by any major reg authority]], ad mandates [where a government may require immunization with a vaccine which still may be EUA, for example]?

[WBG] Given the unprecedented pace of vaccine development, the Bank will accept as the threshold for eligibility of IBRD/IDA resources for vaccine purchase either (i) approval by

Stringent Regulatory Authorities (SRAs) in three regions or (ii) WHO prequalification and approval by 1 SRA*.

[5] [CVEP] Does the WBG program anticipate that multiple COVID-19 vaccines -- with varying profiles [EUA vs major reg approval; safety; efficacy; durability of protection; etc.] -- will be in play in the same country at the same time, with varying constellations over time? This complexity suggests a very dynamic allocation scenario that will change, perhaps continuously, over 2+ years at least...

[WBG] We are working in complexity and a high degree of uncertainty and have developed the programmatic framework with the best available information. As the vaccine landscape continues to develop we take a dynamic view in supporting countries to ensure their programs are adapted to help maximize impact for their populations.

**List of Stringent Regulatory Authorities (SRAs) [WHO]*

...The interim definition of an SRA includes the same elements as the current definition, each qualified by the wording "as before 23 October 2015", as follows:

"A regulatory authority which is:

[a] a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), being the European Commission, the US Food and Drug Administration and the Ministry of Health, Labour and Welfare of Japan also represented by the Pharmaceuticals and Medical Devices Agency (as before 23 October 2015); or

[b] an ICH observer, being the European Free Trade Association, as represented by Swissmedic, and Health Canada (as before 23 October 2015); or

[c] a regulatory authority associated with an ICH member through a legally-binding, mutual recognition agreement, including Australia, Iceland, Liechtenstein and Norway (as before 23 October 2015)."

Currently there are 35 country NRAs [National Regulatory Authorities] which are designated as SRAs: Australia Austria Belgium Bulgaria Canada Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Japan Latvia Liechtenstein Lithuania Luxembourg Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden Switzerland United Kingdom United States of America

.....
.....

COVID 19 Vaccine Development/Regulatory/Distribution Programs Update

[Dr. Reddy's partners with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India](#)

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), Government of India, for advisory support on clinical trials of Sputnik V vaccine in India.

"We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India. We look forward to working with them to accelerate our efforts in bringing the vaccine to India."

The partnership will allow Dr. Reddy's to identify and use some of BIRAC's clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM), implemented by Project Management Unit-NBM at BIRAC. Further, the Company will have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine.

Satish Reddy, Chairman, Dr. Reddy's Laboratories said, "We are pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India. We look forward to working with them to accelerate our efforts in bringing the vaccine to India." ...

.....

Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan

MHLW and Takeda will import and distribute mRNA-1273 in Japan starting in the first half of 2021

October 28, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co., Ltd (NYSE: TAK) have agreed to purchase and distribute 50 million doses of mRNA-1273, Moderna's vaccine candidate against COVID-19, to support Japan's aim of providing vaccines to the Japanese public as soon as possible, subject to necessary regulatory approvals. Moderna is responsible for the manufacture and supply of Moderna's vaccine candidate, and Takeda, with the support of the MHLW, the Japan Agency for Medical Research and Development (AMED) and Moderna, is responsible for all import, local regulatory, development and distribution activities in Japan to ensure timely access starting during the first half of 2021...

.....

UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna's mRNA Vaccine Against COVID-19 (mRNA-1273)

Moderna completed enrollment of its Phase 3 COVE study of mRNA-1273 on October 22

Rolling review based on preclinical, CMC, and clinical data available to date

October 27, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has started the rolling review process of mRNA-1273, the Company's vaccine candidate against COVID-19. This announcement follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the *New England Journal of Medicine*...

.....

[Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 \(mRNA-1273\)](#)

Supply agreement reflects Moderna's commitment to make its vaccine available in Qatar
October 26, 2020

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the Ministry of Public Health of Qatar for mRNA-1273, Moderna's vaccine candidate against COVID-19, to support the Ministry's ongoing efforts to secure early access to a safe and effective COVID-19 vaccine for the people of Qatar...

.....
.....

EMERGENCIES

Coronavirus [COVID-19]

Public Health Emergency of International Concern (PHEIC)

Weekly Epidemiological and Operational updates

last update: 8 October 2020, 20:00 GMT-4

Confirmed cases :: 45 428 731 [week ago: 42 055 863] [two weeks ago: 39 023 292]

Confirmed deaths :: 1 185 721 [week ago: 1 141 567] [two weeks ago: 1 099 586]

Countries, areas or territories with cases :: 219

.....

[Statement on the fifth meeting of the International Health Regulations \(2005\) Emergency Committee regarding the coronavirus disease \(COVID-19\) pandemic](#)

30 October 2020 *Statement*

The fifth meeting of the Emergency Committee convened by the WHO Director-General under the International Health Regulations (IHR) (2005) regarding the coronavirus disease (COVID-19) took place on Thursday, 29 October 2020 from 12:30 to 16:05 Geneva time (CEST).

Proceedings of the meeting

Members and advisors of the Emergency Committee were convened by videoconference...

The Secretariat turned the meeting over to the Chair, Professor Didier Houssin. Professor Houssin also welcomed the Committee and reviewed the objectives and agenda of the meeting.

The WHO Assistant Directors-General for Emergency Response and for Emergency Preparedness and International Health Regulations provided an overview of the current context and an update on the implementation of the 1 August 2020 Temporary Recommendation. WHO continues to assess the global risk level of the COVID-19 pandemic as very high.

The Committee expressed strong appreciation for WHO's leadership and activities throughout the global response. In particular, the Committee appreciated WHO's critical role in developing

evidence-based guidance and recommendations; providing countries with technical assistance and operational support; communicating clear information and addressing misinformation; and convening the Solidarity Trials and the Access to COVID-19 Tools (ACT) Accelerator. The Committee commended WHO's sustained efforts to strengthen national, regional, and global responses to the COVID-19 pandemic.

After ensuing discussion, the Committee unanimously agreed that the pandemic still constitutes an extraordinary event, a public health risk to other States through international spread, and continues to require a coordinated international response. **As such, the Committee considered the COVID-19 pandemic to remain a public health emergency of international concern and offered advice to the Director-General.**

The Director-General determined that the COVID-19 pandemic continues to constitute a PHEIC. He accepted the advice of the Committee to WHO and issued the Committee's advice to States Parties as Temporary Recommendations under the IHR (2005).

The Emergency Committee will be reconvened within three months, at the discretion of the Director-General. The Director-General thanked the Committee for its work.

Advice to the WHO Secretariat **Leadership and Coordination**

1. Continue to coordinate global and regional multilateral organizations, partners, and networks and share best practices for responding to the pandemic.
2. Provide States Parties with a mechanism including templates and processes to report on national progress in implementing the temporary recommendations; collect, analyze, and provide regular updates to the Committee on this progress.

Evidence-Based Response Strategies

3. Continue to provide evidence-based guidance for COVID-19 readiness and response. This guidance should include sustainable long-term response strategies, mitigation approaches for different levels of transmission, refined indicators for risk management and pandemic response, a meta-analysis of the effectiveness of public health and social measures for COVID-19 response, and lessons learned including from intra-action reviews.

Research

4. Continue to convene multi-disciplinary experts to agree on consistent language for and to further explain: all potential modes of transmission and virulence of SARS-CoV-2; severity risk factors and epidemiology of COVID-19; and the striking diversity of the pandemic dynamics globally.
5. Continue intersectoral collaborations to understand the origin of SARS-CoV-2, the role/impact of animals, and provide regular updates on international research findings.
6. Continue to work with partners to refine mathematical models that can inform policy decisions on how best to mitigate the effects of the pandemic.

Surveillance and Contact Tracing

7. Continue to work with partners and networks to provide guidance, tools, and trainings to support countries in strengthening their robust public health surveillance, comprehensive contact tracing, and cluster investigation.

8. Encourage and support countries to understand and report on their epidemiological situation and relevant indicators including through leveraging existing influenza sentinel surveillance systems for COVID-19.

Risk communications and community engagement

9. Continue to work with partners to counter the ongoing infodemic and provide guidance on community mobilization to support effective public health and social measures.

Diagnostics, therapeutics, and vaccines

10. Continue to support development of and equitable access to diagnostics, safe and effective therapeutics and vaccines, through the Access to COVID-19 Tools (ACT) Accelerator; continue to work with all ACT Accelerator partners to provide countries with additional clarity on the processes to enable equitable and timely access to diagnostics, therapeutics, and vaccines, including in humanitarian settings.

11. Accelerate support to enhance countries' readiness for COVID-19 vaccine introduction by providing guidance, tools, and technical assistance for critical areas such as vaccination strategies, vaccine acceptance and demand, training, supply and logistics with a focus on cold chain, and monitoring uptake and vaccine safety.

Health Measures in Relation to International Traffic

12. Continue to work with partners to update and review evidence-based guidance for international travel consistent with IHR (2005) provisions. This guidance should focus on effective, risk-based, and coherent approaches (including targeted use of diagnostics and quarantine) that consider transmission levels, response capacities in origin and destination countries, and relevant travel-specific considerations.

Essential Health Services

13. Work with partners to support countries in strengthening their essential health services, with a particular focus on mental health, public health prevention and control systems, and other societal impacts, as well as preparing for and responding to concurrent outbreaks, such as seasonal influenza. Special attention should continue to be provided to vulnerable settings.

Temporary Recommendations to State Parties

Leadership and coordination

1. Continue to share with WHO best practices, including from intra-action reviews, and apply lessons learned for mitigating resurgence of COVID-19; invest in implementing National Action Plans for sustainable preparedness and response capacities in compliance with the IHR requirements.

2. Report to WHO on progress in implementing the Temporary Recommendations, particularly major achievements, milestones, and obstacles. This information will empower countries, WHO, partners, and the Committee to continue to make informed decisions as the pandemic evolves.

Evidence-Based Response Strategies

3. Avoid politicization or complacency with regards to the pandemic response which negatively impact local, national, regional, and global response efforts. National strategies and localized readiness and response activities should be driven by science, data, and experience and should engage and enable all sectors using a whole-of-society approach.

4. Implement a dynamic risk management approach using appropriate indicators to inform time-limited, evidence-based public health and social measures.

Research

5. Conduct research and share information on transmission, including role of aerosols; presence and potential impact of SARS-CoV-2 in animal populations; and potential sources of contamination (such as frozen products) to mitigate potential risks through preventative measures and international cooperation.

Surveillance and Contact Tracing

6. Sustain efforts to strengthen public health surveillance systems and investments in a trained workforce for active case finding, comprehensive contact tracing, and cluster investigations.

7. Continue timely and consistent reporting to WHO, including through platforms such as GISRS, on all recommended indicators for COVID-19 epidemiology and severity, response measures, and concurrent outbreaks, to enhance global understanding of the pandemic's evolution.

Risk Communications and Community Engagement

8. Engage and empower individuals and communities to strengthen confidence in the COVID-19 response and promote sustained adherence to public health and social measures underpinned by the principles of solidarity and human rights; monitor and address rumours and misinformation.

Diagnostics, Therapeutics, and Vaccines

9. Establish a national multi-disciplinary taskforce, assess progress using the COVID-19 Vaccine Introduction Readiness Assessment Tool (VIRAT), and prepare the National Deployment and Vaccination Plan, which can serve as the holistic operational plan for COVID-19 vaccine introduction. A strong emphasis should be placed on communication with communities to prepare for COVID-19 vaccination.

Health Measures in Relation to International Traffic

10. Regularly re-consider measures applied to international travel in compliance with Article 43 of the IHR (2005) and continue to provide information and rationales to WHO on measures that significantly interfere with international traffic. Ensure that measures affecting international traffic (including targeted use of diagnostics and quarantine) are risk-based, evidence-based, coherent, proportionate and time limited.

11. Continue to strengthen capacity at points of entry to manage potential risks of cross-border transmission and to facilitate international contact tracing.

Essential Health Services

12. Maintain essential health services with sufficient funding, supplies, and human resources; strengthen health systems to cope with mental health impacts of the pandemic, concurrent disease outbreaks, and other emergencies.

.....

WHO Director-General's opening remarks at the media briefing on COVID-19 - 26 October 2020

26 October 2020

:: Last week saw the highest number of COVID-19 cases reported so far. Many countries in the northern hemisphere are seeing a concerning rise in cases and hospitalisations. And intensive care units are filling up to capacity in some places, particularly in Europe and North America. We must do all we can to protect health workers, and the best way to do that is for all of us to take every precaution we can to reduce the risk of transmission, for ourselves and others. No one wants more so-called lockdowns. But if we want to avoid them, we all have to play our part.

:: The fight back against this pandemic is everyone's business. We cannot have the economic recovery we want and live our lives the way we did before the pandemic. We can keep our kids in school, we can keep businesses open, we can preserve lives and livelihoods. We can do it! But we must all make trade-offs, compromises and sacrifices.

:: When leaders act quickly and deliberately, the virus can be suppressed. But, where there has been political division at the national level; where there has been blatant disrespect for science and health professionals, confusion has spread and cases and deaths have mounted. This is why I have said repeatedly: stop the politicisation of COVID-19.

:: Last week WHO conducted its first global e-learning course on health and migration, addressing a critical and often neglected topic of global health. It's vital that all countries include refugees and migrants in their national policies as part of their commitment to universal health coverage.

.....

Weekly epidemiological update - 27 October 2020

Global epidemiological situation

In the past week the highest number of new COVID-19 cases have been reported globally, amounting to over 2 million new cases in the past 7 days (Figure 1), the shortest intervals for this exponential increase since the start of the pandemic, while the number of new deaths is comparable to previous weeks. As of 25 October, over 42 million cases and 1.1 million deaths have been reported globally, with over 2.8 million new cases and nearly 40 000 new deaths reported over the past week.

For the second consecutive week the European Region accounts for the greatest proportion of reported new cases, with over 1.3 million new cases reported this past week – a 33% increase in cases compared to the previous week – contributing nearly half of all new cases reported worldwide this week (46%) (Table 1). Similarly, the number of deaths continues to increase in the region with a 35% increase from last week and accounting for nearly one third of all new deaths globally. Although not as substantial, increases in reported new cases were also observed in the Region of the Americas, Eastern-Mediterranean and African regions. Declines in cases and deaths continued to be reported in the South-East Asia region while the Western Pacific region has shown a slight decline in new cases and deaths in the past 7 days.

Despite regional variations the countries reporting the highest number of cases in the past week remain the same as the previous 3 weeks: India, the United States of America, France, Brazil and the United Kingdom.

Key weekly updates

:: "We are at a critical juncture in this pandemic...We urge leaders to take immediate action, to prevent further unnecessary deaths, essential health services from collapsing and schools shutting again." stressed the WHO Director-General Dr Tedros as part of the regular press briefing on COVID-19 on 23 October. Dr Tedros expanded that as the northern hemisphere enters winter, cases are accelerating, particularly in Europe and North America. The next few months are going to be very tough and some countries are on a dangerous track. WHO is calling on governments to carry out five key actions:

1. Assess the current outbreak situation in your country based on the latest data
2. For those countries where cases, hospitalizations and ICU rates are rising, make the necessary adjustments and course correct as quickly as possible.
3. Be clear and honest with the public about the status of the pandemic in your country and what is needed from every citizen to get through this pandemic together.
4. Put systems in place to make it easier for citizens to comply with the measures that are advised.
5. Improve contact tracing systems and focus on isolating all cases and quarantining contacts, to avoid mandatory stay at home orders for everyone.

:: WHO has updated its draft landscape of COVID-19 candidate vaccines, which lists 44 candidate vaccines in clinical evaluation. At a press briefing last week, Dr Soumya Swaminathan, WHO Chief Scientist, said "We're looking at the beginning of next year really to start seeing data for many of the trials though we may see one or two before the end of the year but the majority will start reporting in early 2021. Many companies are already manufacturing several million doses so as soon as the results are out, if it's promising, companies will be able to start providing those doses to the COVAX facility which will then distribute based on the fair allocation framework that we have developed..."

:: WHO has published an assessment tool for laboratories implementing SARS-CoV-2 testing to assess the capacity of laboratories that have implemented or intend to implement testing for SARS-CoV-2, the virus that causes coronavirus disease (COVID-19)...

.....
.....

Emergencies

POLIO

Public Health Emergency of International Concern (PHEIC)

Polio this week as of 28 October 2020

:: Acknowledging the critical role of leadership in gender mainstreaming, the GPEI launched a Gender Champion for Polio Eradication. Our Champions commit to supporting the GPEI Gender Equality Strategy, highlighting the role of gender in achieving eradication and advocating for its full implementation.

:: In our [latest edition of Coffee with Polio Experts](#), we get to hear from Dr Zubair Wadood on the impact of COVID-19 on the global polio eradication effort, and how the polio infrastructure is supporting COVID response.

Summary of new WPV and cVDPV viruses this week (AFP cases and environmental samples):

:: **Afghanistan:** two WPV1 positive environmental samples and one cVDPV2 positive environmental sample

:: **Pakistan:** 18 WPV1 positive environmental samples and 16 cVDPV2 cases

:: **Cameroon:** two cVDPV2 cases

:: **Chad:** eight cVDPV2 cases

:: **Côte d'Ivoire:** three cVDPV2 cases

:: **Democratic Republic of the Congo (DR Congo):** four cVDPV2 cases

:: **Mali:** 15 cVDPV2 cases

:: **Nigeria:** one cVDPV2 positive environmental sample

:: **South Sudan:** 9 cVDPV2 cases

.....
.....

[WHO Grade 3 Emergencies](#) [to 31 Oct 2020]

[Syrian Arab Republic](#)

:: [WHO Regional Director for the Eastern Mediterranean hands-over medical supplies during his visit to Syria](#)

24 October 2020, Damascus, Syria – A chartered aircraft has landed in Damascus International Airport from the WHO's logistics hub in Dubai, carrying WHO supplies to support the health response in Syria. The 8.8-ton shipment includes medical kits and medicines for almost 2000 beneficiaries and enough personal protective equipment to protect more than 4000 health care workers.

[Democratic Republic of the Congo](#) - *No new digest announcements identified*

[Mozambique floods](#) - *No new digest announcements identified*

[Nigeria](#) - *No new digest announcements identified*

[Somalia](#) - *No new digest announcements identified*

[South Sudan](#) - *No new digest announcements identified*

[Yemen](#) - *No new digest announcements identified*

.....

[WHO Grade 2 Emergencies](#) [to 31 Oct 2020]

[Burkina Faso](#)

:: [Préparation pour une réponse efficace aux situations sanitaires exceptionnelles : Le...](#)
30 octobre 2020

[Afghanistan](#) - *No new digest announcements identified*

[Angola](#) - *No new digest announcements identified*

[Burundi](#) - *No new digest announcements identified*

[Cameroon](#) - *No new digest announcements identified*

Central African Republic - *No new digest announcements identified*
Ethiopia - *No new digest announcements identified*
Iran floods 2019 - *No new digest announcements identified*
Iraq - *No new digest announcements identified*
Libya - *No new digest announcements identified*
Malawi Floods - *No new digest announcements identified*
Measles in Europe - *No new digest announcements identified*
MERS-CoV - *No new digest announcements identified*
Mozambique - *No new digest announcements identified*
Myanmar - *No new digest announcements identified*
Niger - *No new digest announcements identified*
occupied Palestinian territory - *No new digest announcements identified*
HIV in Pakistan - *No new digest announcements identified*
Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements identified*
Sudan - *No new digest announcements identified*
Ukraine - *No new digest announcements identified*
Zimbabwe - *No new digest announcements identified*

.....

WHO Grade 1 Emergencies [to 31 Oct 2020]

Chad - *No new digest announcements identified*
Djibouti - *Page not responding at inquiry*
Kenya - *No new digest announcements identified*
Mali - *No new digest announcements identified*
Namibia - viral hepatitis - *No new digest announcements identified*
Tanzania - *No new digest announcements identified*

.....
.....

UN OCHA – L3 Emergencies

The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.

Syrian Arab Republic

:: Syrian Arab Republic: COVID-19 Humanitarian Update No. 20 As of 29 October 2020

Yemen - *No new digest announcements identified*

.....

UN OCHA – Corporate Emergencies

When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

COVID-19

:: Coronavirus disease 2019 (COVID-19) Situation Report 50: occupied Palestinian territory, issued 29 October 2020, information for period: 5 March - 29 October 2020

East Africa Locust Infestation

:: [Desert Locust situation update - 26 October 2020](#)

Another generation of breeding starts in the Horn of Africa

As expected, the situation remains very critical as more swarms form and a new generation of breeding has now started in Ethiopia and Somalia, which will cause new swarms to form by mid-December that are likely to move southwards and threaten Kenya. Although countries are better prepared compared to a year ago, survey and control operations need to continue to detect and reduce as many infestations as possible. In addition, locusts are increasing along both sides of the southern Red Sea.

.....
.....

WHO & Regional Offices [to 31 Oct 2020]

30 October 2020 *News release*

[As COVID-19 spread accelerates, IHR Emergency Committee urges focus on measures that work](#)

30 October 2020 *Statement*

[Statement on the fifth meeting of the International Health Regulations \(2005\) Emergency Committee regarding the coronavirus disease \(COVID-19\) pandemic](#)

30 October 2020 *Departmental news*

[Start of 1st WHO infodemic management training](#)

29 October 2020 *Departmental news*

[Young people and digital health interventions: working together to design better](#)

29 October 2020 *Country mission*

[Launch of the NCD Investment Case for the Russian Federation: Prevention and control of non-communicable diseases as a catalyst of economic growth and social well-being in Russia](#)

27 October 2020 *Departmental news*

[Beijing+25: where are we now, and where do we go next?](#)

.....

[Weekly Epidemiological Record, 30 October 2020, vol. 95, 44 \(pp. 525–544\)](#)

:: Antigenic and genetic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness

:: WHO seasonal influenza vaccination recommendations during the COVID-19 pandemic

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

No new digest content identified

WHO Region of the Americas PAHO

No new digest content identified

WHO South-East Asia Region SEARO

No new digest content identified

WHO European Region EURO

- :: The challenge of winter during COVID-19 for poor families 30-10-2020
- :: Cities against COVID-19: citizens seek a "better normal" of urban life 30-10-2020
- :: COVID-19: Taking stock and moving forward together 29-10-2020
- :: Roadmap sets direction of Pan-European Commission on Health and Sustainable Development 29-10-2020
- :: WHO delivers emergency medical supplies in response to conflict in and around Nagorno-Karabakh 27-10-2020

WHO Eastern Mediterranean Region EMRO

- :: WHO and partners affirm support to end polio in Pakistan 25 October 2020
- :: Regional Director arrives in Syria, hands-over medical supplies during his visit to Syria 24 October 2020
- :: Health workers celebrated on World Polio Day in Somalia 24 October 2020

WHO Western Pacific Region

- :: Investing in mental health during the COVID-19 pandemic 29 October 2020

.....
.....

CDC/ACIP [to 31 Oct 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

Latest News Releases, Announcements

[CDC Issues Framework for Resuming Safe and Responsible Cruise Ship Passenger Operations](#)

Friday, October 30, 2020

Today the Centers for Disease Control and Prevention (CDC) issued a Framework for Conditional Sailing Order that introduces a phased approach for the safe and responsible resumption of passenger cruises. The Order establishes a framework of actionable items for the cruise line industry to follow so they can resume passenger operations with an emphasis on preventing the further spread of COVID-19 on cruise ships and from cruise ships into communities, and to protect public health and safety. The Order applies to passenger operations on cruise ships with the capacity to carry at least 250 passengers in waters subject to U.S. jurisdiction...

[CDC Opens New South America Regional Office in Brazil](#)

Friday, October 30, 2020

Coronavirus Disease 2019 (COVID-19)

Selected Resources

:: Wear Face Masks on Public Transportation Conveyances and at Transportation Hubs

Thursday, October 29, 2020

:: "Excess Death" Data Point to Pandemic's True Toll Tuesday, October 27, 2020

MMWR News Synopsis Friday, October 30, 2020

:: COVID-19 in a Correctional Facility Employee Following Multiple Brief Exposures to Persons with COVID-19 — Vermont, July–August 2020 (Early release October 21, 2020)

:: Adoption of Strategies to Mitigate Transmission of COVID-19 During a Statewide Primary Election — Delaware, September 2020 (Early release October 23, 2020)

:: COVID-19–Associated Hospitalizations Among Health Care Personnel — COVID-NET, 13 States, March 1–May 31, 2020 (Early release October 26, 2020)

:: COVID-19 Mitigation Behaviors by Age Group — United States, April–June 2020 (Early release October 27, 2020)

:: COVID-19 Outbreak Among a University's Men's and Women's Soccer Teams — Chicago, Illinois, July–August 2020 (Early release October 27, 2020)

:: Trends in the Use of Telehealth During the Emergence of the COVID-19 Pandemic — United States, January–March 2020

:: COVID-19 Outbreak at an Overnight Summer School Retreat — Wisconsin, July–August 2020

:: SARS-CoV-2 Exposure and Infection Among Health Care Personnel — Minnesota, March 6–July 11, 2020

.....

Africa CDC [to 31 Oct 2020]

<http://www.africacdc.org/>

Press Releases

No new digest content identified.

.....

China CDC

<http://www.chinacdc.cn/en/>

No new digest content identified.

National Health Commission of the People's Republic of China

<http://en.nhc.gov.cn/>

News

Oct 31: Daily briefing on novel coronavirus cases in China

On Oct 30, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 33 new cases of confirmed infections.

Vaccine makers might need insurance

2020-10-30

Experts have welcomed a draft regulation on compulsory insurance for Chinese vaccine manufacturers, saying it will better protect the legal rights of vaccine recipients and strengthen oversight of the industry.

The draft regulation, released by the National Medical Products Administration for a month's public consultation earlier this month, includes mandatory liability insurance for all licensed vaccine suppliers on the Chinese mainland to ensure they can provide compensation for recipients injured or killed by substandard vaccines.

It mandates the establishment of a nationwide minimum liability limit, with at least 500,000 yuan (\$74,800) in compensation for a death and indemnities for injuries determined by appraisal results.

"The overall safety and quality of domestic vaccines is well guaranteed. But vaccine products, from China or overseas, always carry inevitable risks, so devising an adequate compensation mechanism in advance is necessary," said Du Yifang, a law professor at Fudan University in Shanghai.

By enlisting insurance firms' mediation in disputes arising from inoculations, people will be able to obtain adequate compensation more quickly and cheaply, she added.

China's Drug Administration Law, which also applies to vaccines, already stipulates that people harmed by substandard drugs are entitled to compensation. However, Yang Yue, a professor at Shenyang Pharmaceutical University in Shenyang, Liaoning province, who specializes in administration of the sector, said vaccine makers would likely struggle to afford such payouts.

"Vaccines are administered to a large number of healthy people, so defective products will result in severe harm and cause large-scale incidents," she said. "In addition to seeking accountability, it is equally significant to deliver assistance to vaccine recipients and protect their legal rights.

"Compulsory insurance of vaccines is thus a crucial tool to spread risks traditionally borne by vaccine makers and add an additional layer of protection for consumers."..

:::::
:::::

Announcements

Paul G. Allen Frontiers Group [to 31 Oct 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

News

No new digest content identified.

BARDA – U.S. Department of HHS [to 31 Oct 2020]

<https://www.phe.gov/about/barda/Pages/default.aspx>

BARDA News

October 28, 2020: HHS, DOD Collaborate on Plans to Purchase of Lilly Investigational Therapeutic to Treat COVID-19

...the U.S. Department of Health and Human Services ([HHS](#)) and Department of Defense ([DoD](#)) today announced an agreement with Eli Lilly and Company to purchase the first doses of the company's COVID-19 investigational antibody therapeutic bamlanivimab, also known as LY-

CoV555. These doses will be available for patient care if the U.S. Food and Drug Administration (FDA) authorizes use of the therapeutic, as outlined in agency guidance...

BMGF - Gates Foundation [to 31 Oct 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 31 Oct 2020]

<https://www.gatesmri.org/>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

No new digest content identified.

CARB-X [to 31 Oct 2020]

<https://carb-x.org/>

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 31 Oct 2020]

<http://cepi.net/>

Latest News

[COVAX welcomes appointment of civil society representatives](#)

Those selected will provide valuable technical expertise and use their experiences in a number of key COVAX groups working to ensure equitable access to COVID-19 vaccines.

COVAX

30 Oct 2020

[See Milestones above for detail]

[Italy pledges first EUR 5 million funding to CEPI to advance COVID-19 vaccine development efforts](#)

Financial contribution is part of a larger donation to support CEPI's work.

COVAX

28 Oct 2020

EDCTP [to 31 Oct 2020]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against

HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

Latest news

No new digest content identified.

Emory Vaccine Center [to 31 Oct 2020]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Medicines Agency [to 31 Oct 2020]

<http://www.ema.europa.eu/ema/>

News & Press Releases

[Extra transparency measures for COVID-19 vaccines and therapeutics](#)

News 30/10/2020

Today the European Medicines Agency (EMA) has implemented two further extra transparency measures for COVID-19 medicines, by publishing both the clinical data in support of the authorisation of Veklury (remdesivir) and information on the COVID-19 treatments and vaccines that have received scientific advice or informal guidance from EMA's pandemic Task Force (COVID-ETF).

These are the latest measures in EMA's drive to maximise the transparency of its regulatory activities on treatments and vaccines for COVID-19...

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee \(PRAC\) 26-29 October 2020](#)

News 30/10/2020

PRAC reviews EMA guidance on risk management plan requirements for COVID-19 vaccines

EMA's safety committee (PRAC) has reviewed the guidance developed by EMA for pharmaceutical companies on how to prepare risk management plans (RMPs) for COVID-19 vaccines.

As for any medicine, companies are required to submit an RMP for COVID-19 vaccines when they apply for a marketing authorisation. Such a plan explains how the company that markets the vaccine must monitor and report on its safety, and what measures they must put in place to manage any risks. Importantly, RMPs are continually updated throughout the lifetime of the vaccine as new information becomes available.

The guidance is for COVID-19 vaccines only and complements the already existing guidelines on the RMP format in the EU, which apply to all medicines.

The guidance will now be sent for adoption to EMA's human medicines committee (CHMP) and will be made public once it is adopted by the CHMP...

European Vaccine Initiative [to 31 Oct 2020]

<http://www.euvaccine.eu/>

Latest News

No new digest content identified.

FDA [to 31 Oct 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>
Press Announcements / Selected Details

[October 30, 2020 - Coronavirus \(COVID-19\) Update: October 30, 2020](#)

[October 30, 2020 - FDA Publishes List of Essential Medicines, Medical Countermeasures, Critical Inputs Required by Executive Order](#)

As the U.S. Food and Drug Administration continues our work to address the current pandemic, we are also looking ahead to prepare for the next potential public health emergency. A recent executive order directed the agency, in consultation with federal partners, to identify a list of essential medicines, medical countermeasures and critical inputs that are medically necessary to have available at all times in an amount adequate to serve patient needs and in the appropriate dosage forms.

The goal of this work is to ensure the American public is protected against outbreaks of emerging infectious diseases, such as COVID-19, as well as chemical, biological, radiological and nuclear threats. To accomplish this goal, the executive order seeks to ensure sufficient and reliable, long-term domestic production of these products, and to minimize potential shortages by reducing our dependence on foreign manufacturers of these products...

[October 28, 2020 - Coronavirus \(COVID-19\) Update: October 28, 2020](#)

[October 26, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup October 26, 2020](#)

FDA - COVID-19 Vaccines [to 31 Oct 2020]

www.fda.gov/covid19vaccines

Upcoming Events

10/27/2020

[I'm the FDA point person on COVID-19 vaccines. We'll make sure they're safe and effective.](#)

FDA Center for Biologics Evaluation and Research Director Dr. Peter Marks

10/27/2020

[FDA Commissioner Stephen Hahn on the Radio: COVID-19 & FDA](#)

FDA Commissioner Stephen Hahn joins a radio morning show to discuss the FDA's role in the fight against COVID-19.

10/27/2020

Fondation Merieux [to 31 Oct 2020]

<http://www.fondation-merieux.org/>

News, Events

Project

[The REDISSE project in West Africa, for the improvement of disease surveillance in ECOWAS countries continues with a second phase](#)

October 29, 2020, Benin, Niger, Nigeria, Mali and Mauritania

The Mériex Foundation starts the second phase of its mandate as part of the REDISSE project aiming at strengthening disease ...

Publication

[HINTT project team publishes results of its multicentered cohort study on tuberculosis](#)

October 26, 2020, Lyon (France)

High white blood cell counts and low lymphocyte proportions before treatment are significantly associated with the risk of tuberculosis treatment ...

Gavi [to 31 Oct 2020]

<https://www.gavi.org/>

News releases

30 October 2020

[COVAX welcomes appointment of civil society representatives](#)

[See Milestones above for detail]

28 October 2020

[Gavi signs statement of intent to procure 200 million doses of Sanofi-GSK COVID-19 vaccine candidate for the COVAX Facility](#)

Geneva, 28 October 2020 – Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies' adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility. The non-binding statement is a critical step toward making sure doses of the vaccine, if approved and licensed, will be made available to all countries and economies participating in the COVAX Facility.

"The signing of this statement of intent is an important step forward in our partnership, and I welcome Sanofi and GSK's commitment to the COVAX goal of equitable access to COVID-19 vaccines," said Seth Berkley, CEO of Gavi. "Gavi is seeking to secure doses of the most promising vaccine candidates – so that the 184 participants involved in the COVAX Facility can make sure their most at-risk groups, such as healthcare workers, have rapid access to doses of a safe and effective vaccine. That is the world's best chance to end the acute stage of this pandemic, and we encourage other vaccine manufacturers to work with us towards that shared global goal."...

27 October 2020

[Myanmar introduces cervical cancer vaccine nationally, despite COVID-19 challenges](#)

:: Around 450,000 girls aged 9-101 will receive the human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer

:: Myanmar currently has the second-highest incidence of cervical cancer in Southeast Asia

:: The vaccine will be rolled out with stringent COVID-19 safety measures in place, including physical distancing and catch-up immunisations for the 73 "stay-at-home townships" currently under tighter restrictions

GHIT Fund [to 31 Oct 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.*

Global Fund [to 31 Oct 2020]

<https://www.theglobalfund.org/en/news/>

News/Updates

[Strategy Development Open Consultation: First Round of Input](#)

30 October 2020

Approximately 250 individuals and groups have contributed to the first round of input into the Open Consultation on the development of the next Global Fund Strategy, a multiyear road map for our partnership's future. Input is synthesized in a new presentation:

Strategy Development Open Consultation Synthesis of First Round of Input
download in [Français](#) | [English](#)

This synthesis covers the responses contributed as of 1 September 2020, which comes from civil society, communities, technical experts, County Coordinating Mechanisms, multilateral partners, bilateral partners, implementers and a range of other stakeholders across regions globally...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 31 Oct 2020]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 31 Oct 2020]

<http://www.hillemanlabs.org/>

No new digest content identified.

Human Vaccines Project [to 31 Oct 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

Press Releases

No new digest content identified.

IAVI [to 31 Oct 2020]

<https://www.iavi.org/newsroom>

PRESS RELEASES

October 27, 2020

[Support from the U.S. Department of Defense Will Accelerate Progress on Vaccine Candidate for COVID-19, IAVI Says](#)

NEW YORK — OCTOBER 27, 2020 — IAVI announced today the award of US\$26.7M from the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to support IAVI's recombinant vesicular stomatitis virus (rVSV) vectored SARS-CoV-2 vaccine candidate. DTRA's commitment will enable critical nonclinical development on the vaccine candidate that

IAVI is developing in partnership with Merck (known as MSD outside the United States and Canada).

DTRA's award will facilitate the vaccine candidate's clinical development path to licensure by supporting work at IAVI's Vaccine Design and Development Laboratory (DDL) in Brooklyn, New York, to characterize immune responses in animals and demonstrate the safety and efficacy profile of rVSVΔG-SARS-CoV-2 vaccination in animals. These nonclinical data will be essential to supplement the clinical data package and to inform the most effective use of the vaccine in an ongoing pandemic. The award from DTRA comes from its Science and Technology New Initiatives, under the topic area Chemical/Biological...

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest content identified.

IFFIm

<http://www.iffim.org/>

Announcements

[IFFIm Appoints Kenneth Lay as Chair of its Board of Directors](#)

29 Oct 2020

Lay succeeds Cyrus Ardalan, who introduced CEPI programme and led successful replenishment raising over US\$ 926 million London, 29 October 2020 – The Board of Directors of the International Finance Facility for Immunisation (IFFIm) has selected Kenneth Lay, a former World Bank executive with extensive capital markets experience, as its next Chair....

[IFFIm Prices US\\$500 Million 3-year Benchmark Vaccine Bonds](#)

29 Oct 2020

IFFIm today priced US\$ 500 million, 3-year fixed rate benchmark Vaccine Bonds that will provide Gavi, the Vaccine Alliance, flexible funding for its core immunisation programmes and efforts to develop and distribute eventual COVID-19 vaccines to countries around the world, particularly the poorest.

[See Milestones above for detail]

IFRC [to 31 Oct 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

Selected Press Releases, Announcements

Azerbaijan

[Azerbaijan Red Crescent Society and IFRC mourn death of volunteer](#)

The Azerbaijan Red Crescent Society and IFRC have today condemned the death of a Red Crescent volunteer who was providing humanitarian assistance in the town of Barda, Azerbaijan.

29 October 2020

Vietnam

Major typhoon devastates areas of central Viet Nam

Kuala Lumpur/Hanoi/Geneva, 29 October 2020 – A major typhoon has devastated areas of central Vietnam, with dozens of people feared dead in tragic landslides in Quang Nam. There are 53 people buried and feared dead in two landslides caused by the storm ...

29 October 2020

Vietnam

Homes of 1 million people in ruin as major typhoon hits Viet Nam

Kuala Lumpur/Hanoi/Geneva, 28 October, 2020 – Catastrophic floods across central Vietnam have already ruined the homes of more than one million people as yet another major storm takes aim for the battered region. In excess of 310,000 homes have been da ...

28 October 2020

Global

Nuclear ban: "Today is an historic day. We call on world leaders to act with courage and join the right side of history"

Geneva/New York, 24 October 2020 – The International Red Cross and Red Crescent Movement welcomes the coming into force of the UN Treaty on the Prohibition of Nuclear Weapons (TPNW). Fifty States have now ratified the Treaty, meaning that it will enter ...

24 October 2020

IRC International Rescue Committee [to 31 Oct 2020]

<http://www.rescue.org/press-release-index>

Media highlights [Selected]

Press Release

The Trump Administration sets new all-time low number for refugee admissions at 15,000 for fiscal year 2021

October 28, 2020

Press Release

The International Rescue Committee warns against worrying rise of misinformation in crisis-affected states, imperiling fight against COVID-19

October 28, 2020

IVAC [to 31 Oct 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 31 Oct 2020]

<http://www.ivi.int/>

Selected IVI News, Announcements, Events

[International Vaccine Institute honored with Minister of Health and Welfare Award for achievements in biosafety](#)

October 28, 2020, SEOUL, Korea — The International Vaccine Institute (IVI) received an award by the Minister of Health and Welfare of the Republic of Korea for achievements in biosafety management...

JEE Alliance [to 31 Oct 2020]

<https://www.jeealliance.org/>

Selected News and Events

No new digest content identified.

MSF/Médecins Sans Frontières [to 31 Oct 2020]

<http://www.msf.org/>

Latest [Selected Announcements]

Coronavirus COVID-19 pandemic

[MSF responds as COVID-19 arrives in Jordan's largest refugee camp](#)

Project Update 28 Oct 2020

Mali

[Prevention is better than cure – vaccinating against measles in Timbuktu](#)

Project Update 27 Oct 2020

... Despite the official end of the war in 2015, Timbuktu region in northern [Mali](#) remains tense, and security incidents and criminality have had a significant impact on people's ability to access healthcare. This in turn has led to low rates of vaccination coverage, especially among children.

Since February, a number of measles cases have been reported in the area and in September Médecins Sans Frontières (MSF), alongside the Ministry of Health, decided to launch a vaccination campaign. The campaign reached over 50,000 children aged between six months and 14 years...

Greece

[Negligent and dangerous COVID-19 response in Vathy camp, Samos](#)

Project Update 26 Oct 2020

Médecins Sans Frontières (MSF) is urging the Greek authorities to immediately scale up their response to COVID-19 in Vathy camp on Samos island and transfer people at high risk to safe accommodation on Greece's mainland or in other EU states.

Vathy camp, which hosts 4,300 people, has registered more than 100 positive cases of COVID-19, yet the authorities have so far failed to put an appropriate medical response in place. Forty asylum seekers in the camp are at risk of developing severe symptoms and at least 10 people have serious medical conditions that cannot be addressed at Samos hospital. Only one army doctor and three nurses are available at the camp...

National Vaccine Program Office - U.S. HHS [to 31 Oct 2020]

<https://www.hhs.gov/vaccines/about/index.html>

No new digest content identified.

NIH [to 31 Oct 2020]

<http://www.nih.gov/news-events/news-releases>

Selected News Releases

[NIH scientists discover key pathway in lysosomes that coronaviruses use to exit cells](#)

October 28, 2020 — Targeting cells' 'trash compactor' could lead to new antiviral strategy to fight COVID-19.

[Scientists use clues in the human genome to discover new inflammatory syndrome](#)

October 27, 2020 — Study used a "search the genome" approach to reveal how mutations in a gene called UBA1 are associated with inflammatory diseases.

PATH [to 31 Oct 2020]

<https://www.path.org/media-center/>

Press Release

[South American countries meet to discuss rollout of new innovations for malaria elimination](#)

October 30, 2020

Experts and policymakers met to review research and plan for the pilot introduction of a new treatment protocol for *P. vivax* malaria in the Americas, against the backdrop of the COVID-19 pandemic.

..."The new tools open a new horizon to eliminate malaria in Brazil, Peru, and Colombia. The feasibility study will be conducted to inform if health services can implement the new treatment scheme. If the results are as expected then we will be able to expand radical cure through these new tools," said Alejandro Llanos-Cuentas, professor at Universidad Peruana Cayetano Heredia.

Brazil, Colombia, and Peru have embraced PAHO's malaria elimination goals but face the challenges of advancing malaria control among hard-to-reach populations in the Amazon and other territories with limited coverage of services. In light of these challenges, there is a desire to explore new tools that may help to increase treatment effectiveness.

As of October 2020, tafenoquine has been approved by the US Food and Drug Administration; Australia's Therapeutic Goods Administration; the Thai Food and Drug Administration; and the Brazilian Regulatory agency (ANVISA). The SD Biosensor STANDARD™ G6PD Test has already been approved in Brazil...

Press Release

[PATH and Wondfo partner to develop a point-of-care rapid diagnostic test for G6PD deficiency](#)

Point-of-care diagnostics for G6PD deficiency, a common hereditary condition, play a critical role in supporting the appropriate treatment of *Plasmodium vivax* malaria

Sabin Vaccine Institute [to 31 Oct 2020]

<http://www.sabin.org/updates/pressreleases>

Statements and Press Releases

[Skoll Foundation Funds Sabin Vaccine Institute, Dalberg and JSI Research & Training Institute, Inc. to Establish COVID-19 Vaccine Equity Project](#)

October 28, 2020

As COVID-19 vaccine developers generate clinical evidence of safety and effectiveness needed for vaccine approval, this project will help prepare for the efficient and equitable distribution of vaccines globally by ensuring that national immunization programs have the resources and health systems in place to achieve sustainable global protection from COVID-19 by 2022 and strengthen capacity for vaccination across the life span...

The COVID-19 Vaccine Equity Project will comprise three phases designed to rapidly assess vaccine distribution landscape, maximize learnings and scale a successful pilot to enable equitable global delivery of vaccines. The Skoll Foundation is funding Phases 1 and 2. In Phase 1 ("Plan"), the group will collaborate with Sabin's Boost Community members to coordinate with ACT-A and select the four countries in which to pilot the project. In Phase 2 ("Pilot"), all three partners will work hand-in-hand with national and subnational immunization professionals to analyze the pilot countries' needs regarding vaccine financing, procurement and distribution; leading to the creation of tailored action plans for equitable delivery of COVID-19 vaccines. As additional funders join the project, these action plans will serve as a blueprint for Phase 3, in which a successful pilot will be scaled to more than 40 countries and expanded beyond COVID-19 vaccines to strengthen life-course immunization; an approach that prioritizes timely and effective vaccination throughout the lifespan...

UNAIDS [to 31 Oct 2020]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

30 October 2020

[UNAIDS saddened by the death of Valentin Pokrovsky, a Russian leader on HIV, medicine and pandemic preparedness](#)

30 October 2020

[Bringing HIV and COVID-19 testing services to hard-to-reach areas in Uzbekistan](#)

29 October 2020

[Working with allies to keep comprehensive sexuality education alive](#)

27 October 2020

[COVID-19's impact on HIV vertical transmission services reversed](#)

26 October 2020

[Key populations have suboptimal knowledge of their HIV status](#)

UNICEF [to 31 Oct 2020]

<https://www.unicef.org/media/press-releases>

Selected Press releases, Statements

Statement

10/29/2020

[UNICEF Executive Director Henrietta Fore's remarks at Indiana University on "Access to Learning for the World's Children: Reimagining Education for the Post-COVID World"](#)

Checked against delivery

Press release

10/28/2020

[Children in the poorest countries have lost nearly four months of schooling since start of pandemic – UNESCO, UNICEF and World Bank report finds](#)

New report looks at national education responses to COVID-19 including lost learning; remote learning support for students, parents and teachers; school reopening plans; health protocols; and financing

Statement

10/27/2020

[UNICEF Executive Director Henrietta Fore's remarks at the World Health Summit Panel "Accelerating the SDG-3 Global Action Plan for Health and Wellbeing"](#)

As prepared for delivery

Press release

10/27/2020

[Malnutrition surges among young children in Yemen as conditions worsen](#)

One in five children under the age of five in parts of Yemen are estimated to be acutely malnourished and in urgent need of treatment as malnutrition cases increase across the south, UN agencies warn

Unitaid [to 31 Oct 2020]

<https://unitaid.org/>

Featured News

27 October 2020

[Delivering innovation for children](#)

A technology landscape by Unitaid and WHO

Children continue to suffer disproportionately from preventable and treatable diseases such as tuberculosis, malaria, HIV and co-morbidities in low- and middle-income countries.

One of the reasons behind this is the lack of availability of child-friendly health products, despite recent progress in tackling these diseases.

The new [technology landscape](#) released by Unitaid, in collaboration with WHO, provides an overview of existing and pipeline technologies that could better allow for more effective administration of essential medicines to children. The report highlights potential opportunities to apply innovation to critical formulations that meet the unique needs of children.

"The landscape shows the untapped potential to innovate and tackle the challenges facing millions of children needing to take medicine and affected by the deadliest infectious diseases," said Dr Philippe Duneton, Unitaid Executive Director. "Unitaid, WHO and its partners are exploring which innovative delivery systems could enable faster access to better-tailored treatments for children".

26 October 2020

[UnitaidExplore keeps seeking!](#)

26 October 2020

UnitaidExplore is looking to improve child health outcomes by developing better delivery systems for children's medicines for use in low resource settings. Delivery and formulation solutions of interest may include—but are not limited to! —micro-needles, supportive technologies such as taste-masking, enhancement of bioavailability, and others described in the Unitaid landscape [Innovative Delivery Systems for Paediatrics Medicines](#). UnitaidExplore aims to support transformative solutions and we are open to diverse technologies; surprise us!

[Press Release on the appointment of Dr Philippe Duneton as Unitaid's new Executive Director](#)

26 October 2020

Geneva – The Unitaid Executive Board is delighted to announce the appointment of Dr Philippe Duneton as Executive Director.

Dr Duneton played an essential role in the founding of Unitaid as well as in the numerous successes achieved by the organization since then. He has been acting Executive Director since March 2020 and has been instrumental in leading Unitaid's response to the COVID-19 pandemic...

Vaccination Acceptance Research Network (VARN) [to 31 Oct 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

Announcements

No new digest content identified.

Vaccine Confidence Project [to 31 Oct 2020]

<http://www.vaccineconfidence.org/>

Research and Reports

No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 31 Oct 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

[Vaccine Update for Providers](#)

October 2020

:: December 2020 event [Registration is now open](#) for the Dec. 9, 2020, Current Issues in Vaccines webinar. Dr. Offit's presentation will be an **Update on SARS-CoV-2 vaccines**

The event will start at noon ET, and free continuing education credits will be offered for the live and archived event (CME, CEU, and CPE).

Wellcome Trust [to 31 Oct 2020]

<https://wellcome.ac.uk/news>

Opinion | 29 October 2020

[A look inside the global partnership that's working to find and deliver Covid-19 treatments](#)

Paul Schreier, Chief Operating Officer, Wellcome

Finding and delivering Covid-19 treatments worldwide requires global collaboration at an unprecedented scale. Paul Schreier describes how the ACT-Accelerator Therapeutics Partnership works and what it needs to achieve its mission.

The Wistar Institute [to 31 Oct 2020]

<https://www.wistar.org/news/press-releases>

Press Releases

Oct. 29, 2020

[Wistar Creates a New Synthetic DNA Vaccine Against Powassan Virus](#)

Vaccine protects animals against tick-borne Powassan virus, an emerging infectious disease.

WFPHA: World Federation of Public Health Associations [to 31 Oct 2020]

<https://www.wfpha.org/>

Latest News

No new digest content identified.

World Organisation for Animal Health (OIE) [to 31 Oct 2020]

<https://www.oie.int/en/for-the-media/press-releases/2020/>

Press Releases

26/10/20

[OIE and FAO kickstart global initiative to stop spread of deadly pig disease](#)

.....

ARM [Alliance for Regenerative Medicine] [to 31 Oct 2020]

<https://alliancerm.org/press-releases/>

Press Releases

No new digest content identified.

BIO [to 31 Oct 2020]

<https://www.bio.org/press-releases>

Press Releases

[New Strategic Vision for Biotechnology Innovation Organization](#)

October 27, 2020

The Biotechnology Innovation Organization (BIO) today announced a new, strategic direction that will help guide it to achieving long-term goals while maintaining responsiveness to changing political headwinds...

After at least 106 one-on-one conversations with member companies, extensive strategic planning sessions, a broad membership survey and several focus groups, BIO outlined the new direction through

- :: a new mission – to drive a bio revolution through education, collaboration, and advocacy,
- :: a new purpose – to cure patients, protect our climate and to nourish humanity; and

:: a new vision – a world of rapid biotech innovation that is equitably harnessed for health, sustainability and justice.

BIO plans to execute on the strategic direction through five different pillars:

[1] Be a voice of science and for science.

[2] Unite and empower biotech innovators and their ecosystem to improve lives.

[3] Remove barriers to innovation.

[4] Champion broad access to biotech breakthroughs and scientific quality.

[5] Catalyze resilient and sustainable bio-based economies.

The Board and staff of the nearly 1000-member organization plan to operationalize the five pillars beginning immediately. For more information on BIO's new strategic direction, visit www.bio.org/strategic-vision.

DCVMN – Developing Country Vaccine Manufacturers Network [to 31 Oct 2020]

<http://www.dcvmn.org/>

News; Upcoming events

[DCVMN Annual General Meeting \(Virtual\): Vaccines, a healthy future](#)

3 November 2020 to 5 November 2020

ICBA – International Council of Biotechnology Associations [to 31 Oct 2020]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 31 Oct 2020]

<http://www.ifpma.org/resources/news-releases/>

Selected Press Releases, Statements, Publications

No new digest content identified.

PhRMA [to 31 Oct 2020]

<http://www.phrma.org/>

Selected Press Releases, Statements

Press Release

[The latest: What they are saying: Intellectual property protections vital to incentivize ongoing COVID-19 research and development](#)

Tom Wilbur | October 28, 2020

* * * *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and

other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 11, 2020 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 22, Number 10: E831-905 October 2020

<https://journalofethics.ama-assn.org/issue/caring-native-americans>

[Reviewed earlier]

American Journal of Infection Control

October 2020 Volume 48, Issue 10, p1133-1286

<http://www.ajicjournal.org/current>

[Reviewed earlier]

American Journal of Preventive Medicine

October 2020 Volume 59, Issue 4, p469-620

<http://www.ajpmonline.org/current>

[Reviewed earlier]

American Journal of Public Health

October 2020 110(S3) Supplement 3 2020

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 103, Issue 4, October 2020

<http://www.ajtmh.org/content/journals/14761645/103/4>

[Reviewed earlier]

Annals of Internal Medicine

20 October 2020 Volume 173, Issue 8

<http://annals.org/aim/issue>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 288 November 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/288/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMJ Global Health

October 2020 - Volume 5 - 10

<https://gh.bmj.com/content/5/10>

[Reviewed earlier]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 31 Oct 2020)

[Ethics and the marketing authorization of pharmaceuticals: what happens to ethical issues discovered post-trial and pre-marketing authorization?](#)

In the EU, clinical assessors, rapporteurs and the Committee for Medicinal Products for Human Use are obliged to assess the ethical aspects of a clinical development program and include major ethical flaws in the marketing authorization deliberation processes. To this date, we know very little about the manner that these regulators put this obligation into action. In this paper, we intend to look into the manner and the extent that ethical issues discovered during inspection have reached the deliberation processes.

Authors: Rosemarie D. L. C. Bernabe, Ghislaine J. M. W. van Thiel, Nancy S. Breekveldt, Christine C. Gispen and Johannes J. M. van Delden

Content type: Research article

27 October 2020

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMC Research Notes

<http://www.biomedcentral.com/bmcrenotes/content>

(Accessed 31 Oct 2020)

[No new digest content identified]

BMJ Open

October 2020 - Volume 10 - 10

<https://bmjopen.bmj.com/content/10/10>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 98, Number 10, October 2020, 645-724

<https://www.who.int/bulletin/volumes/98/10/en/>

[Reviewed earlier]

Child Care, Health and Development

Volume 46, Issue 6 Pages: 651-750 November 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

Clinical Pharmacology & Therapeutics

Volume 108, Issue 4 Pages: 681-895 October 2020

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

Clinical Therapeutics

September 2020 Volume 42 Issue 9 p1625-1846, e161-e208

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

Clinical Trials

Volume 17 Issue 5, October 2020

<https://journals.sagepub.com/toc/ctja/17/5>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 31 Oct 2020]

[No new digest content identified]

Contemporary Clinical Trials

Volume 96 September 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/96/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 3, Issue 5 / October 2020

<https://www.liebertpub.com/toc/crispr/3/5>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 8, issue 3, September 2020

<https://link.springer.com/journal/40142/volumes-and-issues/8-3>

[Reviewed earlier]

Current Opinion in Infectious Diseases

October 2020 - Volume 33 - Issue 5

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

Developing World Bioethics

Volume 20, Issue 3 Pages: 115-171 September 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

Development in Practice

Volume 30, Issue 6, 2020

<http://www.tandfonline.com/toc/cdip20/current>

New sectoral perspectives on international NGOs: scale, dynamics and influences.

Guest Editors: Nicola Banks, Lau Schulpen, and Dan Brockington

[Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 14 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 44, Issue 4 Pages: 619-752 October 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

EMBO Reports

Volume 21 Issue 10 5 October 2020

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 26, Number 10—October 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

Epidemics

Volume 32 September 2020

<https://www.sciencedirect.com/journal/epidemics/vol/32/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 42, Issue 5 Pages: 1-40 September–October 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

Participants with autism :: Big data and pragmatic trials :: Covid-19 research

[Reviewed earlier]

The European Journal of Public Health

Volume 30, Issue 5, October 2020

<https://academic.oup.com/eurpub/issue/30/5>

Viewpoints

[The first 10 000 COVID-19 papers in perspective: are we publishing what we should be publishing?](#)

Anna Odone, Sandro Galea, David Stuckler, Carlo Signorelli, the University Vita-Salute San Raffaele COVID-19 literature monitoring working group

European Journal of Public Health, Volume 30, Issue 5, October 2020, Pages 849–850,

<https://doi.org/10.1093/eurpub/ckaa170>

[In search of the relevant COVID research](#)

Peter Allebeck, Alma Sörberg Wallin

European Journal of Public Health, Volume 30, Issue 5, October 2020, Pages 850–851,

<https://doi.org/10.1093/eurpub/ckaa169>

[COVID-19 and human rights—why should the public health community be concerned?](#)

David Patterson, Dineke Zeegers Paget

European Journal of Public Health, Volume 30, Issue 5, October 2020, Pages 852–853,

<https://doi.org/10.1093/eurpub/ckaa174>

Vaccination

[Measles outbreak in Romania: understanding factors related to suboptimal vaccination uptake](#)

Katrine Bach Habersaat, Adriana Pistol, Aurora Stanescu, Catherine Hewitt, Miljana Grbic ...

European Journal of Public Health, Volume 30, Issue 5, October 2020, Pages 986–992,

<https://doi.org/10.1093/eurpub/ckaa079>

[Examining vaccination coverage in Germany: spatiotemporal clustering of MMR coverage, 2008–14](#)

Cory N Spencer, Paul L Delamater

European Journal of Public Health, Volume 30, Issue 5, October 2020, Pages 993–995,

<https://doi.org/10.1093/eurpub/ckaa120>

Expert Review of Vaccines

Vol 19 (8) 2020

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 31 Oct 2020]

[No new digest content identified]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 31 Oct 2020]

[No new digest content identified]

Global Health Action

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=toCList>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 8, No. 3 October 01, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

Global Public Health

Volume 15, 2020 Issue 11

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 31 Oct 2020]

[No new digest content identified]

Health Affairs

Vol. 39, No. 10 October 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

Children's Health

Health and Human Rights

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

Special Section: Mental Health and Human Rights

[Reviewed earlier]

Health Economics, Policy and Law

Volume 15 - Issue 4 - October 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 35, Issue 8, October 2020

<https://academic.oup.com/heapol/issue/35/8>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 31 Oct 2020]

[No new digest content identified]

Human Gene Therapy

Volume 31, Issue 19-20 / October 2020

<https://www.liebertpub.com/toc/hum/31/19-20>

[New issue; No digest content identified]

Humanitarian Exchange Magazine

Number 78, October 2020

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

[Disability inclusion in humanitarian action](#)

by HPN October 2020

The theme of this edition of Humanitarian Exchange, co-edited with Sherin Alsheikh Ahmed from Islamic Relief Worldwide, is disability inclusion in humanitarian action. Persons with disabilities are not only disproportionately impacted by conflicts, disasters and other emergencies, but also face barriers to accessing humanitarian assistance. At the same time, global commitments and standards and the IASC Guidelines on the inclusion of persons with disabilities in humanitarian action all emphasise how persons with disabilities are also active agents of change. Disability and age-focused organisations have led on testing and demonstrating how inclusion can be done better. Yet despite this progress, challenges to effective inclusion remain.

As Kirstin Lange notes in the lead article, chief among these challenges is humanitarian agencies' lack of engagement with organisations of persons with disabilities. Simone Bula, Elizabeth Morgan and Teresa Thomson look at disability inclusion in humanitarian response in the Pacific, and Kathy Al Jubeh and Alradi Abdalla argue for a 'participation revolution', building on learning from the gender movement. Tchaurea Fleury and Sulayman AbdulMumuni Ujah outline how the Bridge Article 11 training initiative is encouraging constructive exchange between humanitarian and disability actors. The lack of good, disaggregated data is highlighted

by Sarah Collinson; Frances Hill, Jim Cranshaw and Carys Hughes emphasise the need for training resources in local languages and accessible formats; and Sophie Van Eetvelt and colleagues report on a review of the evidence on inclusion of people with disabilities and older people.

Rebecca Molyneux and co-authors analyse the findings of a review of a DFID programme in north-east Nigeria, while Carolin Funke highlights the importance of strategic partnerships between disability-focused organisations, drawing on her research in Cox's Bazar. Sherin Alsheikh Ahmed describes Islamic Relief Worldwide's approach to mainstreaming protection and inclusion, while Pauline Thivillier and Valentina Shafina outline IRC's Client Responsive Programming. The edition ends with reflections by Mirela Turcanu and Yves Ngunzi Kahashi on CAFOD's SADI approach.

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 16, Issue 9, 2020

<http://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/content>

[Accessed 31 Oct 2020]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 31 Oct 2020]

[Moving from rhetoric to action: how Africa can use scientific evidence to halt the COVID-19 pandemic](#)

The ongoing pandemic of the coronavirus disease 2019 has spread rapidly to all countries of the world. Africa is particularly predisposed to an escalation of the pandemic and its negative impact given its weak economy and health systems. In addition, inadequate access to the social determinants of health such as water and sanitation and socio-cultural attributes may constrain the implementation of critical preventive measures such as hand washing and social distancing on the continent.

Authors: Olushayo Oluseun Olu, Joy Luba Lomole Waya, Sylvester Maleghemi, John Rumunu, David Ameh and Joseph Francis Wamala

Content type: Commentary

28 October 2020

International Health

Volume 12, Issue 5, September 2020

<https://academic.oup.com/inthealth/issue/12/5>

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol 7, No 10 (2020) October 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/67>

[Reviewed earlier]

International Journal of Epidemiology

Volume 49, Issue 3, June 2020

<https://academic.oup.com/ije/issue/49/3>

[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 13 Issue 4 2020

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/4>

Table of Contents

[Reviewed earlier]

International Journal of Infectious Diseases

September 2020 Volume 98, p1-502

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0010-5](https://www.ijidonline.com/issue/S1201-9712(20)X0010-5)

[Reviewed earlier]

JAMA

October 27, 2020, Vol 324, No. 16, Pages 1589-1690

<https://jamanetwork.com/journals/jama/currentissue>

Viewpoint September 10, 2020

[Fairly Prioritizing Groups for Access to COVID-19 Vaccines](#)

Govind Persad, JD, PhD; Monica E. Peek, MD, MPH, MS; Ezekiel J. Emanuel, MD, PhD

free access has active quiz has multimedia has audio

JAMA. 2020;324(16):1601-1602. doi:10.1001/jama.2020.18513

This Viewpoint proposes that ethical principles of preventing harm, helping disadvantaged populations, and achieving equal treatment should guide COVID-19 vaccine distribution, supporting initial allocation to health care workers, people in high-risk occupations and housing, and those with high-risk medical conditions.

JAMA Network

[COVID-19 Update October 31, 2020](#)

These articles on COVID-19 were published across the JAMA Network in the last week.

JAMA Pediatrics

October 2020, Vol 174, No. 10, Pages 919-1012

<http://archpedi.jamanetwork.com/issue.aspx>

[Reviewed earlier]

JBI Database of Systematic Review and Implementation Reports

October 2020 - Volume 18 - Issue 10

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

October 2020 Volume 67, Issue 4, p461-622

[https://www.jahonline.org/issue/S1054-139X\(20\)X0008-5](https://www.jahonline.org/issue/S1054-139X(20)X0008-5)

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 69 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

Journal of Community Health

Volume 45, issue 5, October 2020

<https://link.springer.com/journal/10900/volumes-and-issues/45-5>

Articles

[Reviewed earlier]

Journal of Development Economics

Volume 147 November 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/147/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 15 Issue 4, October 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

October 2020 - Volume 74 - 10

<https://jech.bmj.com/content/74/10>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 13, Issue 3 Pages: 179-249 August 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>
[Reviewed earlier]

Journal of Global Ethics

Volume 16, Issue 2, 2020

<http://www.tandfonline.com/toc/rjge20/current>
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 31, Number 3, August 2020

<https://muse.jhu.edu/issue/42831>
[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 22, issue 5, October 2020

<https://link.springer.com/journal/10903/volumes-and-issues/22-5>
[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 18, 2020_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>
[New issue; No digest content identified]

Journal of Infectious Diseases

Volume 222, Issue 3, 1 August 2020

<https://academic.oup.com/jid/issue/222/3>
[Reviewed earlier]

Journal of Medical Ethics

October 2020 - Volume 46 - 10

<http://jme.bmj.com/content/current>
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 7, Issue 4 (2020)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>
[New issue; No digest content identified]

Journal of Pediatrics

October 2020 Volume 225, p1-288

<http://www.jpeds.com/current>
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

<https://joppp.biomedcentral.com/>
[Accessed 31 Oct 2020]
[No new digest content identified]

Journal of Public Health Management & Practice

September/October 2020 - Volume 26 - Issue 5
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>
[Reviewed earlier]

Journal of Public Health Policy

Volume 41, Issue 3, September 2020
<https://link.springer.com/journal/41271/41/3>
[Reviewed earlier]

Journal of Refugee & Global Health

Volume 3, Issue 1 (2020)
<https://ir.library.louisville.edu/rgh/>
[Reviewed earlier]

Journal of the Royal Society – Interface

October 2020 Volume 17 Issue 171
<https://royalsocietypublishing.org/toc/rsif/current>
[Reviewed earlier]

Journal of Travel Medicine

Volume 27, Issue 6, August 2020
<https://academic.oup.com/jtm/issue/27/6>
[Reviewed earlier]

Journal of Virology

November 2020; Volume 94, Issue 21
<http://jvi.asm.org/content/current>
[Reviewed earlier]

The Lancet

Oct 31, 2020 Volume 396 Number 10260 p1373-1462, e64-e72

<https://www.thelancet.com/journals/lancet/issue/current>
[New issue; No digest content identified]

The Lancet Child & Adolescent Health

Oct 2020 Volume 4 Number 10 p709-794, e36-e39
<https://www.thelancet.com/journals/lanchi/issue/current>
[Reviewed earlier]

Lancet Digital Health

Oct 2020 Volume 2 Number 10 e493-e560
<https://www.thelancet.com/journals/landig/issue/current>
[Reviewed earlier]

Lancet Global Health

Oct 2020 Volume 8 Number 10 e1242-e1351
<http://www.thelancet.com/journals/langlo/issue/current>
[Reviewed earlier]

Lancet Infectious Diseases

Oct 2020, Volume 20 Number 10 p1101-1216, e250-e283
<http://www.thelancet.com/journals/laninf/issue/current>
[Reviewed earlier]

Lancet Public Health

Oct 2020 Volume 5 Number 10 e512-e567
<https://www.thelancet.com/journals/lanpub/issue/current>
[Reviewed earlier]

Lancet Respiratory Medicine

Oct 2020 Volume 8 Number 10 p935-1060, e73-e77
<http://www.thelancet.com/journals/lanres/issue/current>
[Reviewed earlier]

Maternal and Child Health Journal

Volume 24, issue 10, October 2020
<https://link.springer.com/journal/10995/volumes-and-issues/24-10>
[Reviewed earlier]

Medical Decision Making (MDM)

Volume 40 Issue 7, October 2020

<http://mdm.sagepub.com/content/current>
[New issue; No digest content identified]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy

Volume 98, Issue 3 Pages: 619-1020 September 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

Nature

Volume 586 Issue 7831, 29 October 2020

http://www.nature.com/nature/current_issue.html

African diversity

Although Africa is regarded as the cradle of modern humans, only a fraction of the genetic diversity among African individuals has been surveyed. In this week's issue, [Zané Lombard](#), [Adebowale Adeyemo](#), [Neil Hanchard](#) and their colleagues from the H3Africa Consortium help to redress this imbalance by presenting whole-genome sequence analyses of 426 individuals covering 50 ethnolinguistic groups. The researchers uncovered more than three million new variants, mostly among newly sampled groups, and identified 62 previously unreported genes associated with viral immunity, DNA repair and metabolism. They also observed complex patterns of ancestral mixing within and between populations, and found evidence that Zambia was a likely intermediate site along the routes of expansion for Bantu-speaking populations. The findings help to refine understanding of migration across the African continent and identify gene flow and response to disease as strong drivers of genome-level population variation. The cover shows a subset of the genetic data collected in the study translated into hand-loomed beaded necklaces by the Marigold beadwork cooperative in Zimbabwe.

Editorial | 28 October 2020

[**Africa's people must be able to write their own genomics agenda**](#)

Genomics on the continent is finally getting the attention it deserves from international donors — but more funding needs to come from national and regional sources, too.

Perspective | 28 October 2020

[**Strategic vision for improving human health at The Forefront of Genomics**](#)

In this Perspective, authors from the National Human Genome Research Institute (NHGRI) present a vision for human genomics research for the coming decade.

Eric D. Green, Chris Gunter[...]¹ & Teri A. Manolio

Article | 28 October 2020

[**High-depth African genomes inform human migration and health**](#)

Whole-genome sequencing analyses of African populations provide insights into continental migration, gene flow and the response to human disease, highlighting the importance of including diverse populations in genomic analyses to understand human ancestry and improve health.

Ananyo Choudhury, Shaun Aron[...]¹ & Neil A. Hanchard

Article | 21 October 2020

[Exome sequencing and characterization of 49,960 individuals in the UK Biobank](#)

Exome sequences from the first 49,960 participants in the UK Biobank highlight the promise of genome sequencing in large population-based studies and are now accessible to the scientific community.

Cristopher V. Van Hout, Ioanna Tachmazidou[...] & Aris Baras

Article | 14 October 2020

[Evidence for 28 genetic disorders discovered by combining healthcare and research data](#)

By integrating healthcare and exome-sequencing data from parent–offspring trios of patients with developmental disorders, 28 genes that had not previously been associated with developmental disorders were identified.

Joanna Kaplanis, Kaitlin E. Samocha[...] & Kyle Retterer

Article | 14 October 2020

[Inherited causes of clonal haematopoiesis in 97,691 whole genomes](#)

Analysis of 97,691 high-coverage human blood DNA-derived whole-genome sequences enabled simultaneous identification of germline and somatic mutations that predispose individuals to clonal expansion of haematopoietic stem cells, indicating that both inherited and acquired mutations are linked to age-related cancers and coronary heart disease.

Alexander G. Bick, Joshua S. Weinstock[...] & Pradeep Natarajan

Nature Biotechnology

Volume 38 Issue 10, October 2020

<https://www.nature.com/nbt/volumes/38/issues/10>

SARS-CoV-2 detection

[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 31 Oct 2020)

[No new digest content identified]

Nature Genetics

Volume 52 Issue 10, October 2020

<https://www.nature.com/ng/volumes/52/issues/10>

[Reviewed earlier]

Nature Medicine

Volume 26 Issue 10, October 2020

<https://www.nature.com/nm/volumes/26/issues/10>

Patient-partnered clinical research

The path to productive collaboration between researchers and patients is not always easy, with language differences, knowledge gaps and power dynamics setting considerable barriers along the way. In this issue, we explore how patient- and community-led research is achievable if both sides make it a priority. The cover, designed by illustrator Sarah Lippett, a person living with a rare disease who explores her diagnostic odyssey in her work, shows how effective and equitable patient–researcher collaboration can be transformative to research.

[Reviewed earlier]

Nature Reviews Genetics

Volume 21 Issue 10, October 2020

<https://www.nature.com/nrg/volumes/21/issues/9>

[Reviewed earlier]

Nature Reviews Immunology

Volume 20 Issue 10, October 2020

<https://www.nature.com/nri/volumes/20/issues/10>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 19 Issue 10, October 2020

<https://www.nature.com/nrd/volumes/19/issues/10>

[Reviewed earlier]

New England Journal of Medicine

October 29, 2020 Vol. 383 No. 18

<http://www.nejm.org/toc/nejm/medical-journal>

Perspective

[Developing Safe and Effective Covid Vaccines — Operation Warp Speed’s Strategy and Approach](#)

Moncef Slaoui, Ph.D., and Matthew Hepburn, M.D.

Perspective

[Up Is Down — Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine Approval](#)

Jerry Avorn, M.D., and Aaron S. Kesselheim, M.D., J.D., M.P.H.

Pediatrics

Vol. 146, Issue 4 1 Oct 2020

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

Pharmaceutics

Volume 12, Issue 7 (July 2020) – 97 articles
<https://www.mdpi.com/1999-4923/12/7>
[Reviewed earlier]

PharmacoEconomics

Volume 38, issue 10, October 2020
<https://link.springer.com/journal/40273/volumes-and-issues/38-10>
[Reviewed earlier]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>
(Accessed 31 Oct 2020)
[No new digest content identified]

PLoS Medicine

<http://www.plosmedicine.org/>
(Accessed 31 Oct 2020)

Collection Review

[The intersection of genomics and big data with public health: Opportunities for precision public health](#)

Muin J. Khoury, Gregory L. Armstrong, Rebecca E. Bunnell, Juliana Cyril, Michael F. Iademarco
| published 29 Oct 2020 PLOS Medicine
<https://doi.org/10.1371/journal.pmed.1003373>

Summary points

:: The field of precision public health (PPH) has emerged as a response to the increasing availability of genomics, biobanks, and other sources of big data in healthcare and public health.

:: The field has evolved starting with genomics to include multiple practical applications such as pathogen genomics that address population health.

:: PPH can expand understanding of health disparities, advance strategic public health science, and demonstrate the need for innovation and workforce development.

:: In the coronavirus disease 2019 (COVID-19) era, rapidly evolving scientific innovation can have a long-lasting impact on PPH beyond the pandemic.

:: Further developments in PPH will require global, national, and local leadership and stakeholder engagement.

[Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study](#)

Hannah Lawrence, Harry Pick, Vadsala Baskaran, Priya Daniel, Chamira Rodrigo, Deborah Ashton, Rochelle C. Edwards-Pritchard, Carmen Sheppard, Seyi D. Eletu, David Litt, Norman K. Fry, Samuel Rose, Caroline Trotter, Tricia M. McKeever, Wei Shen Lim
Research Article | published 23 Oct 2020 PLOS Medicine
<https://doi.org/10.1371/journal.pmed.1003326>

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 31 Oct 2020)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

Research Article

[Common childhood vaccines do not elicit a cross-reactive antibody response against SARS-CoV-2](#)

Ahmed Kandeil, Mokhtar R. Gomaa, Ahmed El Taweel, Ahmed Mostafa, Mahmoud Shehata, Ahmed E. Kayed, Omnia Kutkat, Yassmin Moatasim, Sara H. Mahmoud, Mina Nabil Kamel, Noura M. Abo Shama, Mohamed El Sayes, Rabeh El-Shesheny, Mahmoud A. Yassien, Richard J. Webby, Ghazi Kayali, Mohamed A. Ali

Research Article | published 28 Oct 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0241471>

[Country-level pandemic risk and preparedness classification based on COVID-19 data: A machine learning approach](#)

Jordan J. Bird, Chloe M. Barnes, Cristiano Premebida, Anikó Ekárt, Diego R. Faria

Research Article | published 28 Oct 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0241332>

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 31 Oct 2020]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America

<http://www.pnas.org/content/early/>

Front Matter

[Opinion: For now, it's unethical to use human challenge studies for SARS-CoV-2 vaccine development](#)

Jeffrey P. Kahn, Leslie Meltzer Henry, Anna C. Mastroianni, Wilbur H. Chen, and Ruth Macklin

PNAS first published October 29, 2020. <https://doi.org/10.1073/pnas.2021189117>

[Fine-scale spatial clustering of measles nonvaccination that increases outbreak potential is obscured by aggregated reporting data](#)

Nina B. Masters, Marisa C. Eisenberg, Paul L. Delamater, Matthew Kay, Matthew L. Boulton, and Jon Zelner

PNAS first published October 26, 2020. <https://doi.org/10.1073/pnas.2011529117>

Prehospital & Disaster Medicine

Volume 35 - Issue 5 - October 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 139 October 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/139/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

14 October 2020 Volume 287 Issue 1936

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 187 Pages A1-A2, 1-190 (October 2020)

<https://www.sciencedirect.com/journal/public-health/vol/187/suppl/C>

[Reviewed earlier]

Public Health Ethics

IN PROGRESS

Volume 13, Issue 1, April 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Reports

Volume 135 Issue 5, September/October 2020

<https://journals.sagepub.com/toc/phrg/135/5>

[Reviewed earlier]

Qualitative Health Research

Volume 30 Issue 12, October 2020

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

Research Ethics

Volume 16 Issue 3-4, July-October 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 31 Oct 2020]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

Latest articles

29 Oct 2020

[**Just societies: A new vision for health equity in the Americas after COVID-19**](#)

Editorial | English |

29 Oct 2020

[**The Health Equity Network of the Americas: inclusion, commitment, and action**](#)

Current topic | Spanish |

29 Oct 2020

[**Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian survey**](#)

Original research | English |

28 Oct 2020

[**Theoretical and practical challenges of proportionate universalism: a review**](#)

Review | English |

28 Oct 2020

[**Civil society promoting government accountability for health equity in the Caribbean: The Healthy Caribbean Coalition**](#)

Special report | English |

Risk Analysis

Volume 40, Issue 9 Pages: 1691-1886 September 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[Reviewed earlier]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 31 Oct 2020]

Perspectives

[**Guaranteeing the Health Rights of People with Disabilities in the COVID-19 Pandemic: Perspectives from China**](#)

Qi F, Wang Q

Risk Management and Healthcare Policy 2020, 13:2357-2363

Published Date: 30 October 2020

Science

30 October 2020 Vol 370, Issue 6516
<http://www.sciencemag.org/current.dtl>
{New issue; No digest content identified}

Science Translational Medicine

28 October 2020 Vol 12, Issue 567
<https://stm.sciencemag.org/>
{New issue; No digest content identified}

Social Science & Medicine

Volume 262 October 2020
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/262/suppl/C>
[Reviewed earlier]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>
[Accessed 31 Oct 2020]
[No new digest content identified]

Travel Medicine and Infectious Diseases

Volume 37 September–October 2020
<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/37/suppl/C>
[Reviewed earlier]

Tropical Medicine & International Health

Volume 25, Issue 10 Pages: i-iv, 1167-1305 October 2020
<https://onlinelibrary.wiley.com/toc/13653156/current>
[Reviewed earlier]

Vaccine

Volume 38, Issue 47 Pages 7409-7568 (3 November 2020)
<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/47>
Research article Abstract only

[Influenza vaccination policies for health workers in low-income and middle-income countries: A cross-sectional survey, January–March 2020](#)

Helena C. Maltezos, Kalliopi Theodoridou, Maria Tseroni, Vasilios Raftopoulos, ... Philipp Lambach
Pages 7433-7439

Research article Abstract only

[The determinants of vaccine hesitancy in China: A cross-sectional study following the Changchun Changsheng vaccine incident](#)

Fanxing Du, Tracey Chantler, Mark R. Francis, Fiona Yueqian Sun, ... Zhiyuan Hou
Pages 7464-7471

Research article Open access

[How acceptable is adolescent self-consent for the HPV vaccination: Findings from a qualitative study in south-west England](#)

Suzanne Audrey, Michelle Farr, Marion Roderick, Karen Evans, Harriet Fisher
Pages 7472-7478

Research article Abstract only

[Utility of the Tétanos Quick Stick® in the vaccine catch-up of adult migrants without proof of prior vaccination](#)

Sandrine Adeikalam, Hélène de Champs Léger, Nicolas Vignier, Sophie Grabar, Dominique Salmon
Pages 7517-7525

Research article Abstract only

[Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial](#)

Mbayame Niang, Meagan E. Deming, Deborah Goudiaby, Ousmane M. Diop, ... Kathleen M. Neuzil
Pages 7526-7532

Vaccines — Open Access Journal

<http://www.mdpi.com/journal/vaccines>

(Accessed 31 Oct 2020)

Open Access Review

[Vaccine Prices: A Systematic Review of Literature](#)

by [Rabia Hussain](#), [Nadeem Irfan Bukhari](#), [Anees ur Rehman](#), [Mohamed Azmi Hassali](#) and [Zaheer-Ud-Din Babar](#)

Vaccines 2020, 8(4), 629; <https://doi.org/10.3390/vaccines8040629> - 29 Oct 2020

Abstract

Vaccines are among the most vital interventions to control and reduce the morbidity and mortality worldwide. In accessing vaccines, pricing is usually the single most important deciding element. However, there is a scarcity of the literature on the vaccines pricing. The current study aims to review vaccine prices from the published literature and to evaluate factors that impact the pricing of vaccines. The literature (from 2015–2020) was reviewed to identify the original research articles. Systematic searches were conducted across the five databases including, Google Scholar, PubMed, Science Direct, Scopus and Springer Link. Literature search yielded 23,626 articles, of which 7351 were screened and 7310 articles were excluded based on title and abstracts relevance. The 41 studies were selected for full text review and 4 studies were found to meet the inclusion criteria. The included studies discussed vaccine prices for childhood vaccines, for Human Papilloma Virus (HPV) in US, China and in Europe. One study detailed the

various scenarios of the HPV vaccines pricing. It was found that recently introduced vaccines have higher prices owing to the involvement of technology and research for their manufacture. However, prices tended to decrease over some maturation in price and by the involvement of Global Alliance for Vaccine Initiative (GAVI) and other allies. The prices of vaccines in China were much lower than the other high-income countries and the prices offered through United Nations Children's Fund (UNICEF), mainly due to the large scale of demand in China. The affordable prices of vaccines were related to delicate procedures involving multiple stakeholders and a shorter duration of contract. This review systematically evaluated the literature and identified key factors that could impact vaccines pricing. The prices were higher for the newly introduced vaccines into the market. However, with the price maturation, there was a decline in the pricing and affordable prices could be achieved through tender pricing and involvement of GAVI and other allies

Open Access Article

Value Frameworks for Vaccines: Which Dimensions Are Most Relevant?

by Jeroen Luyten, Roselinde Kessels, Corinne Vandermeulen and Philippe Beutels
Vaccines 2020, 8(4), 628; <https://doi.org/10.3390/vaccines8040628> - 28 Oct 2020

Viewed by 197

Abstract

In addition to more narrow criteria such as safety, effectiveness and cost-effectiveness, vaccines can also be evaluated based on broader criteria such as their economic impact, contribution to disease eradication objectives, caregiver aspects, financial protection offered, equity or social acceptability. We summarize a survey executed in a sample of the population (n = 1000) in Flanders, Belgium, in which we investigated support for using these broader criteria to evaluate vaccines for funding decisions. By means of both favourable and unfavourable framings of a hypothetical vaccine across 40 value dimensions, we find support for the view that people indeed consider a broad range of medical and socio-economic criteria relevant. Several of these are not incorporated in standard evaluation frameworks for vaccines. The different results we find for different framings highlight the importance of developing a consistent a priori value framework for vaccine evaluation, rather than evaluating vaccines on an ad hoc basis.

Value in Health

October 2020 Volume 23, Issue 10, p1281-1402

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0012-X](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0012-X)

[Reviewed earlier]

*

*

*

*

Media/Policy Watch

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

The Atlantic

<http://www.theatlantic.com/magazine/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

BBC

<http://www.bbc.co.uk/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

The Economist

<http://www.economist.com/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

Financial Times

<https://www.ft.com/>

Accessed 31 Oct 2020

[Moderna rakes in over \\$1bn in deposits for potential Covid vaccine](#)

...Moderna has received more than \$1bn in deposits from governments for its potential Covid-19 vaccine, highlighting how the pandemic has transformed the fortunes of the loss-making US biotech.

October 29, 2020

Forbes

<http://www.forbes.com/>

Accessed 31 Oct 2020

Oct 30, 2020

[Report Details 'Shocking' Outbreaks Of Mumps, Influenza, And Chickenpox In ICE Detention Centers](#)

Rare infections are spreading in ICE centers that have crowded conditions and poor access to healthcare.

By Robert Hart Forbes Staff

Oct 29, 2020

[The FDA Will Not Inspect Vaccine Production Plants](#)

Approval of a vaccine by the Food and Drug Administration (FDA) typically requires inspection of the vaccine's manufacturing plants. In a Covid-19 world, this will not be the case. Covid-19 vaccine candidates will get a pass on FDA plant inspections, according to Bloomberg.

By William A. Haseltine Contributor

Oct 29, 2020

[Fauci Endorses National Mask Mandate But Concedes It's Unlikely Under Trump](#)

The nation's top infectious disease official says he hasn't spoken about the outbreak with President Trump in 'quite a while.'

By [Andrew Solender](#) Forbes Staff

Foreign Affairs

<http://www.foreignaffairs.com/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

Foreign Policy

<http://foreignpolicy.com/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

The Guardian

<http://www.guardiannews.com/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

New Yorker

<http://www.newyorker.com/>

Accessed 31 Oct 2020

[No new, unique, relevant content]

New York Times

<http://www.nytimes.com/>

Accessed 31 Oct 2020

Asia Pacific

[U.S. Says Virus Can't Be Controlled. China Aims to Prove It Wrong.](#)

China's approach to keep Covid-19 at bay has helped restore confidence and allowed businesses to reopen. But it is a strategy steeped in authoritarianism.

By Javier C. Hernández Oct. 30

Washington Post

<https://www.washingtonpost.com/>

Accessed 31 Oct 2020

[States say they lack federal funds to distribute coronavirus vaccine as CDC tells them to be ready](#)

Lena H. Sun · Health · Oct 30, 2020

* * * *

[Think Tanks et al](#)

Brookings

<http://www.brookings.edu/>

Accessed 31 Oct 2020

TechStream

[Will Americans trust a COVID-19 vaccine? Not if politicians tell them to.](#)

Sarah Kreps and Douglas L. Kriner

Friday, October 30, 2020

...In a study of American attitudes toward COVID-19 vaccination, just published in the Journal of the American Medical Association Network Open, we found that Americans' support for vaccination declines in the face of political involvement in the vaccine process...

Center for Global Development [to 31 Oct 2020]

<http://www.cgdev.org/page/press-center>

Event

[COVID-19 Vaccine Predictions Part 2: Estimating the Time Before We Approve Efficacious](#)

11/10/20

Much of the discussion around society's ability to return to "normality" after the COVID-19 pandemic has centered on the development of a vaccine. This has led to unprecedented collaboration and investment.

Chatham House [to 31 Oct 2020]

<https://www.chathamhouse.org/>

[No new relevant content]

CSIS

<https://www.csis.org/>

Accessed 31 Oct 2020

Podcast Episode

[Delivering Vaccines to Americans: Cause for Alarm?](#)

October 28, 2020 | By J. Stephen Morrison, H. Andrew Schwartz

Council on Foreign Relations

<http://www.cfr.org/>

Accessed 31 Oct 2020

[No new relevant content]

Kaiser Family Foundation

https://www.kff.org/search/?post_type=press-release

Accessed 31 Oct 2020

[No new relevant content]

* * * *

* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * *
* * * *